Publications by authors named "Na-Yun Su"
Article Synopsis
- Bismuth quadruple therapy (BQT) effectively eradicates Helicobacter pylori infection, but its impact on gut microbiota and the role of fecal microbiota transplant (FMT) post-therapy remains less understood.
- A randomized controlled trial conducted in China involved 30 H. pylori-positive patients who received either FMT or a placebo after 14 days of BQT, with stool samples analyzed to assess changes in gut microbiota.
- Results showed that BQT temporarily decreased beneficial gut bacteria and increased pathogenic ones, with both groups returning to baseline gut flora levels by Week 10, and the FMT group showing reduced gastrointestinal symptoms compared to the placebo group by Week 3.
Background: According to the Maastricht VI/Florence consensus report, potassium-competitive acid blockers (P-CAB) may improve Helicobacter pylori eradication treatment.
Materials And Methods: A total of 213 H. pylori treatment-naive patients aged between 18 and 70 years were treated with two regimens.
Background: Potassium-competitive acid blockers (P-CAB) are recommended for the treatment of Helicobacter pylori infections, but dual therapy of P-CAB with amoxicillin has been poorly studied. The current study compared the efficacy, adverse reactions, compliance, and effects on gut microbiota of 14-day vonoprazan-amoxicillin (VA) dual therapy with esomeprazole, bismuth potassium citrate, amoxicillin, and metronidazole (EBAM) quadruple therapy in treatment-naive patients with H. pylori.
View Article and Find Full Text PDFBackground: A high-dose proton pump inhibitor (PPI)-amoxicillin dual therapy has been investigated for treatment of patients with () infection. Currently, the efficacy of this dual therapy remains inconclusive, with controversial findings from various single-center clinical trials.
Objectives: To assess the efficacy and safety of high-dose dual therapy (HDDT) compared with the bismuth-containing quadruple therapy (BQT) in treatment-naive patients with infection.
Article Synopsis
- * A total of 146 patients with previous treatment failures were enrolled in a randomized controlled trial, receiving either HDDT (high doses of esomeprazole and amoxicillin) or various regimens based on individual bacterial resistance for CB-SGT, all for 14 days.
- * Eradication rates for HDDT and CB-SGT were comparable, both around 84.9%, with HDDT achieving slightly higher success in patients with certain genetic polymorphisms, but the difference was within acceptable limits